RT Journal Article
SR Electronic
T1 NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 4671
OP 4674
VO 61
IS 12
A1 Kurashige, Takushi
A1 Noguchi, Yuji
A1 Saika, Takashi
A1 Ono, Toshiro
A1 Nagata, Yasuhiro
A1 Jungbluth, Achim
A1 Ritter, Gerd
A1 Chen, Yao-Tseng
A1 Stockert, Elisabeth
A1 Tsushima, Tomoyasu
A1 Kumon, Hiromi
A1 Old, Lloyd J.
A1 Nakayama, Eiichi
YR 2001
UL http://cancerres.aacrjournals.org/content/61/12/4671.abstract
AB NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY-ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ. ©2001 American Association for Cancer Research.